# Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

> **NCT00088907** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 270 (actual)

## Conditions studied

- Recurrent Head and Neck Cancer
- Metastatic Head and Neck Cancer

## Interventions

- **DRUG:** docetaxel
- **OTHER:** placebo
- **DRUG:** gefitinib

## Key facts

- **NCT ID:** NCT00088907
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** 2009-05
- **Final completion:** 2012-08
- **Target enrollment:** 270 (ACTUAL)
- **Why stopped:** It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.
- **Last updated:** 2015-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088907, "Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00088907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*